DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION

用于抑制 HIV-1 的双亲和力重新靶向 (DART) 分子

• 批准号: 10452465
• 负责人: JEFFREY NORDSTROM
• 金额: $ 628.8万
• 依托单位: MACROGENICS, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-15 至 2023-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10452465
• 关键词: AIDS prevention; AIDS/HIV problem; Address; Affinity; Anti-Retroviral Agents; Antibodies; Binding; Biological Products; Biological Response Modifier Therapy; Bone Marrow Transplantation; Clinical Research; Clinical Trials; Complement; Contractor; Development; Disease remission; Drug Combinations; Engineering; Epidemic; HIV; HIV Antibodies; HIV Entry Inhibitors; HIV vaccine; HIV-1; Human; Immune; Immunotherapeutic agent; Immunotherapy; Infection; Mediating; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Newborn Infant; Outcome; Patients; Persons; Property; Research; Safety; Specificity; Technology; Testing; Therapeutic; Therapeutic Agents; Treatment Efficacy; Vaccine Design; Vaccines; Viral Load result; Virus; Work; antiretroviral therapy; attenuation; base; improved; innovation; interest; neutralizing antibody; novel; programs; research clinical testing

NIAID is committed to research necessary to end the HIV/AIDS epidemic and in finding new and more effective immune based therapies that complement antiretroviral drug combinations (cART). HIV prevention vaccines are designed to address outcomes of exposure in uninfected persons, i.e. acquisition of virus or attenuation of viral load when infection occurs. Thus far, such vaccines have not demonstrated therapeutic efficacy when used in infected subjects. Thus the need exists for innovative therapeutic biological products that work in infected persons. Recent research has also identified numerous anti-HIV neutralizing antibodies with properties that suggest they may be useful as therapeutic agents. These antibodies have useful and novel properties including potency, broad ranges of neutralization, and other antibody-mediated effector functions. Additional research indicates certain antibodies may be engineered to improve binding specificity, potency, or antibody effector function. There is also heightened interest in the possibility of HIV eradication or sustained remission based on one apparent HIV cure due to therapeutic bone marrow transplant, and one apparent cure due to immediate and aggressive antiretroviral therapy in a newborn. There is also a specific interest in therapeutic anti-HIV vaccine, anti-HIV antibody products, or other immune-based anti-HIV products being part of a cure armamentarium to be tested as part of HIV sustained suppression/eradication human clinical trials to determine safety and efficacy.

NIAID致力于结束艾滋病毒/艾滋病流行所需的研究，并寻找新的和更有效的免疫疗法，以补充抗逆转录病毒药物组合（cART）。艾滋病毒预防疫苗旨在解决未感染者暴露的结果，即感染发生时病毒的获得或病毒载量的减弱。 到目前为止，当用于受感染的受试者时，此类疫苗尚未显示出治疗功效。因此，需要在感染者中起作用的创新治疗性生物产品。最近的研究还确定了许多抗HIV中和抗体，其特性表明它们可能用作治疗剂。这些抗体具有有用和新颖的性质，包括效力、广泛的中和作用和其它抗体介导的效应子功能。另外的研究表明某些抗体可以被工程化以改善结合特异性、效力或抗体效应子功能。人们还高度关注艾滋病毒根除或持续缓解的可能性，这是基于治疗性骨髓移植导致的一种明显的艾滋病毒治愈，以及新生儿立即和积极的抗逆转录病毒治疗导致的一种明显治愈。 还特别关注治疗性抗HIV疫苗、抗HIV抗体产品或其他基于免疫的抗HIV产品，其作为待作为HIV持续抑制/根除人类临床试验的一部分进行测试以确定安全性和有效性的治疗设备的一部分。